Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Life expectancy exceeds 3 months * The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard. Exclusion Criteria: * small cell lung cancer or small cell lung cancer * Currently involved in interventional clinical research or treatment, or have received other research drugs or used research equipment within 4 weeks prior to the first dose; * Previously received the following treatments: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or synergistically inhibit T cell receptors (eg, CTLA-4, OX-40, CD137);